Head-to-head · WeighScore
Call-On-Doc vs Ilant Health
The verdict
Call-On-Doc takes it — 61.3/100 to 56.8/100.
Call-On-Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Call-On-Doc is a large multi-condition online telehealth service (2M+ patients, 800k+ five-star reviews) offering a GLP-1 weight-loss program.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Call-On-Doc | Ilant Health |
|---|---|---|
| WeighScore | 61.3/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #297 | #407 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #297 · C
Strengths
- Prescribes branded GLP-1s (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda)
- Available in all 50 states plus DC
- Fast, no-appointment visits usually completed within two hours
- Patients can use insurance at the pharmacy plus an Rx savings card
- Large, well-reviewed platform (2M+ patients, 800k+ 5-star reviews)
Where it loses points
- Specific visit fee and medication pricing not posted on homepage
- Credit card required for the visit fee
- Multi-condition focus rather than weight-loss specialist
- Provider credentials described only generically
Graded #407 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.